An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its first quarter 2023 investor update conference call on May 4, 2023, at 8:30 a.m. Eastern Time. Participants can join by calling (888) 330-2384 (U.S./Canada) or (240) 789-2701 (international) with conference ID 4671230. The call will also be accessible via webcast on the company's website, which is recommended to access at least 15 minutes prior to the start time. A replay of the call will be available starting at 11:30 a.m. Eastern Time on the same day, and can be accessed until May 18, 2023, by calling (800) 770-2030 (U.S./Canada) or (647) 362-9199 (international), also using conference ID 4671230. Ironwood Pharmaceuticals is focused on advancing treatments for gastrointestinal diseases.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 4, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
The call will be available for replay via telephone starting Thursday, May 4, 2023 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, May 18, 2023. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (647) 362-9199 (international) using conference ID number 4671230. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.
We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.
